

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE BY SECURED PARTY		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Credit Suisse AG as successor to Credit Suisse First Boston		01/31/2011	bank: SWITZERLAND
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	King Pharmaceuticals Research and Development, Inc. as successor to Jones Pharma Incorporated		
<b>Street Address:</b>	4000 Centre Green Way		
<b>City:</b>	Cary		
<b>State/Country:</b>	NORTH CAROLINA		
<b>Postal Code:</b>	27513		
<b>Entity Type:</b>	CORPORATION: DELAWARE		
<b>PROPERTY NUMBERS Total: 11</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
Registration Number:	0874778	PULMONAIRE	
Registration Number:	1393762	TUSSIGON	
Registration Number:	1652129	THEREVAC	
Registration Number:	1657982	LIQUI-CHAR	
Registration Number:	1810413		
Registration Number:	2016089	LEVOXYL	
Registration Number:	2044605	THROMBIN-JMI	
Registration Number:	2167335	CYTOMEL	
Registration Number:	2158841		
Registration Number:	1619385	VANEX-HD	
Registration Number:	1742709	DP	
<b>CORRESPONDENCE DATA</b>			

CH \$290.00 0874778

Fax Number: (202)778-5299  
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*  
Phone: 202.662.5299  
Email: trademarks@cov.com  
Correspondent Name: Kathleen T. Gallagher-Duff, Esq.  
Address Line 1: 1201 Pennsylvania Avenue, N.W.  
Address Line 4: Washington, DISTRICT OF COLUMBIA 20004

ATTORNEY DOCKET NUMBER:	029459.0030
NAME OF SUBMITTER:	Cheryl L. Fountain/Paralegal Specialist
Signature:	/cherylfountain/
Date:	02/02/2011

Total Attachments: 3  
source=King RD 2002 Security Agreement TM Release#page1.tif  
source=King RD 2002 Security Agreement TM Release#page2.tif  
source=King RD 2002 Security Agreement TM Release#page3.tif

## Release of Security Interest in Trademarks

January 31, 2011

**WHEREAS**, KING PHARMACEUTICALS, INC., a Tennessee corporation, as Borrower, certain of its subsidiaries, as Guarantors, and CREDIT SUISSE AG, as successor to Credit Suisse First Boston, Cayman Islands branch (“**Credit Suisse**”), in its capacity as Collateral Agent for the Secured Parties (as each term is defined in the Security Agreement (as defined below)), entered into that certain Security Agreement (the “**Security Agreement**”) dated as of April 23, 2002;

**WHEREAS**, the Security Agreement was recorded with the United States Patent and Trademark Office on October 2, 2002 on Reel No. 002592, Frame No. 0382;

**WHEREAS**, under the Security Agreement, King Pharmaceuticals Research and Development, Inc. as successor to Jones Pharma Incorporated (the “**Assignee**”) granted to Credit Suisse a security interest in certain Collateral (as defined in the Security Agreement), including those items set forth on Schedule 1 (collectively, the “**Released Trademark Collateral**”);

**WHEREAS**, the parties agree and acknowledge that the foregoing United States Patent and Trademark Office assignment record may list Credit Suisse AG in a capacity other than Collateral Agent, and that the security interest was granted to, and this release is correctly made by, Credit Suisse, as Collateral Agent; and

**WHEREAS**, Credit Suisse desires to release the security interest granted by the Assignee under the Security Agreement in the Released Trademark Collateral.

**NOW, THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Credit Suisse, as Collateral Agent for the Secured Parties, does hereby unconditionally, irrevocably and absolutely terminate, release, extinguish and forever discharge the security interest granted under the Security Agreement in the Released Trademark Collateral, together with all of the goodwill of the business connected with the use of, or symbolized by, such Released Trademark Collateral, and hereby unconditionally, irrevocably and absolutely assigns, transfers and conveys to the Assignee all right, title and interest of Credit Suisse in, to and under such Released Trademark Collateral and such goodwill granted under the Security Agreement. This Release of Security Interest in Trademarks shall be binding upon Credit Suisse’s legal representatives, assigns and successors, and upon the Secured Parties and their legal representatives, assigns and successors. Credit Suisse also hereby authorizes, and requests, the Director of the United States Patent and Trademark Office or his delegate to record this Release of Security Interest in Trademarks against the Released Trademark Collateral.

*[signature page to follow]*

IN WITNESS WHEREOF, Credit Suisse has caused this Release of Security Interest in Trademarks to be duly executed by its officers thereunto duly authorized as of the day and year first above written.

CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH

By:

Name:

Title:

By:

Name:

Title:

[signature page – King Pharmaceuticals Research and Development, Inc. trademark release]

**Schedule 1**

**KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. AS  
SUCCESSOR TO JONES PHARMA INCORPORATED**

**U.S. TRADEMARK REGISTRATIONS**

<b>Trademark</b>	<b>Registration No.</b>	<b>Registration Date</b>
PULMONAIRE	874778	August 12, 1969
TUSSIGON	1393762	May 20, 1986
THEREVAC	1652129	July 30, 1991
LIQUI-CHAR	1657982	September 24, 1991
Enema Design	1810413	December 14, 1993
LEVOXYL	2016089	November 12, 1996
THROMBIN-JMI	2044605	March 11, 1997
CYTOMEL	2167335	June 23, 1998
Levoxyl Tablet Design	2158841	May 19, 1998
VANEX-HD	1619385	October 30, 1990
DP (Design)	1742709	December 29, 1992